WBTS Forum http://wbts-forum.org// Mon, 26 Apr 2021 07:54:38 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.1 http://wbts-forum.org//wp-content/uploads/2021/04/default1.png WBTS Forum http://wbts-forum.org// 32 32 Netflix and Amazon appear in Greensill Bank court file http://wbts-forum.org//netflix-and-amazon-appear-in-greensill-bank-court-file/ http://wbts-forum.org//netflix-and-amazon-appear-in-greensill-bank-court-file/#respond Mon, 26 Apr 2021 07:53:00 +0000 http://wbts-forum.org//netflix-and-amazon-appear-in-greensill-bank-court-file/ White Oak is named in a list of creditors and counterparties in US bankruptcy court filings by German Greensill Bank administrator Michael Frege in attempts to be recognized as a “foreign main proceeding” and ensure control of the bank’s US assets. A hearing will be held in New York on May 12. German directors and […]]]>


White Oak is named in a list of creditors and counterparties in US bankruptcy court filings by German Greensill Bank administrator Michael Frege in attempts to be recognized as a “foreign main proceeding” and ensure control of the bank’s US assets. A hearing will be held in New York on May 12.

German directors and prosecutors reacted swiftly to Greensill Bank, a direct subsidiary of the Australian parent company of Greensill Capital, upon its liquidation.

Bremen prosecutors, who are investigating whether the bank can prove the existence of debts it bought from GFG, raided the offices and homes of former Greensill bankers last week, according to Reuters.

The main activity of the Bremen-based bank, which had 137 employees in Germany, was to purchase receivables from international trade finance transactions through the UK operations of Greensill Capital, which it financed with billions of dollars of deposits received from bank customers.

Other groups cited in Greensill Bank court filings include coal miner Bluestone Resources, which is suing Greensill; food company Cargill; the electricity suppliers Xcel Energy and NRG Energy; steelmakers like ArcelorMittal USA and Nippon Steel North America; and the streaming service Netflix as well as Amazon Digital Services.

Many of these companies, including Bluestone Resources, Cargill, NRG Energy, ArcelorMittal, NipponSteel and Amazon, are listed as the underlying entities of the receivables held in Credit Suisse supply chain funds that have been aggregated into securities. by Greensill Capital.

The privately held Cargill owns a large trading and capital markets firm that provides trade finance to its business partners, including suppliers and buyers.

This includes structured trade finance which provides financing to “financial institutions and businesses based in emerging markets,” Cargill said in the jobs postings.

Greensill Bank’s Australian and UK assets have already been frozen after Mr Frege obtained legal approvals in early April to prevent their sale, escalating the war on Greensill Capital’s assets, including invoices owed by GFG.

Separate court documents listing the creditors of the US firm of Greensill Capital show the Peter Greensill Family Trust, to which Greensill’s Australian parent company owes $ 78 million, is represented by Brisbane-based restructuring specialist Scott Butler, partner at Hall law firm & Willcox.

Mr Butler, who chairs the Insolvency and Restructuring Committee of the Law Council of Australia, confirmed The Australian Financial Review that he had been retained by the Peter Greensill Family Trust.

Peter Greensill is the brother of Lex Greensill and Lex Greensill is a beneficiary of the trust.



Source link

]]>
http://wbts-forum.org//netflix-and-amazon-appear-in-greensill-bank-court-file/feed/ 0
GBPEUR could see the pressure after Friday’s collapse http://wbts-forum.org//gbpeur-could-see-the-pressure-after-fridays-collapse/ http://wbts-forum.org//gbpeur-could-see-the-pressure-after-fridays-collapse/#respond Mon, 26 Apr 2021 07:44:08 +0000 http://wbts-forum.org//gbpeur-could-see-the-pressure-after-fridays-collapse/ The GBPEUR exchange rate fell back below the 1.15 level on Friday to mark the fourth consecutive day of losses for the pound sterling. Highs near 1.1650 have been dropped and the British pound may come under further pressure this week after a second failure at these levels. GBP / EUR is trading at 1.1475 […]]]>


The GBPEUR exchange rate fell back below the 1.15 level on Friday to mark the fourth consecutive day of losses for the pound sterling. Highs near 1.1650 have been dropped and the British pound may come under further pressure this week after a second failure at these levels.

GBP / EUR is trading at 1.1475 early in the day for a slight gain of 0.05%. Germany released key economic data this week, while the eurozone will see its first estimate of GDP in the first quarter.

German and euro data to guide the week

Pound-to-Euro traders may have to wait until the middle of the week for a clear direction on the pair as the German economy sees consumer confidence ease. These numbers are analyzed in the context of lockdowns and case rates, so they’re not really driving the market, but any deviation will matter. That day will also see an interest rate decision from the US Federal Reserve and there is the potential for volatility in the market in general. Canada made a surprise move to gradually reduce its bond purchases last week, which could see markets move if the Fed signals something similar. This would put pressure on the ECB and BoE as they move towards reopening their own economies.

Thursday will be a big day for the GBP / EUR exchange rate with employment and inflation figures in Germany. Analysts expect inflation to rise 0.1%, while the job market is expected to post a labor loss of 2k due to ongoing lockdowns.

Friday is another big day for the single currency with flash estimates of GDP for the first quarter from Germany, Italy and the eurozone. This will be the main driver of sterling and euro rates over the medium term, as it will show whether the eurozone is on track to match growth estimates in a slow move toward reopening their economies. Core inflation for Europe will also be released on that day, but it is expected to remain stable.

American travelers return to Europe

American tourists who have been fully vaccinated against the coronavirus will be allowed to travel to the European Union this summer, according to the New York Times.

US travelers have been barred from non-essential travel to the EU for a year due to the pandemic. Many European countries see millions of American tourists every year and the current leak is hurting the tourism industry and employment levels. The United States has seen a strong deployment of vaccines and it is becoming clear that a two-tier system is emerging, with only the vaccinated being allowed to travel overseas to Western countries.

The EU’s vaccination program will have enough doses to cover 70% of adults by the end of July, according to European Commission chief Ursula von der Leyen. This is an improvement over the target of the previous September.

The GBPEUR could dip to the 1.14 test this week with higher support levels at 1.1280 which was a key level in the pound’s upside 2020 move.



Source link

]]>
http://wbts-forum.org//gbpeur-could-see-the-pressure-after-fridays-collapse/feed/ 0
Swiss bank pays to settle German tax evasion investigation http://wbts-forum.org//swiss-bank-pays-to-settle-german-tax-evasion-investigation/ http://wbts-forum.org//swiss-bank-pays-to-settle-german-tax-evasion-investigation/#respond Mon, 26 Apr 2021 07:28:37 +0000 http://wbts-forum.org//swiss-bank-pays-to-settle-german-tax-evasion-investigation/ Some Germans appear to have used Migros Bank to hide assets from their national tax authorities. © Keystone / Gaétan Bally Swiss bank Migros has agreed to pay 2.4 million euros (2.65 million francs) to resolve cross-border tax evasion issues with Germany. This content was published on April 26, 2021 – 9:28 a.m. April 26, […]]]>


Some Germans appear to have used Migros Bank to hide assets from their national tax authorities. © Keystone / Gaétan Bally

Swiss bank Migros has agreed to pay 2.4 million euros (2.65 million francs) to resolve cross-border tax evasion issues with Germany.

This content was published on April 26, 2021 – 9:28 a.m.

swissinfo.ch/mga

Migros is one of several Swiss banks to have imposed a sanction to avoid prosecution in the neighboring country. Other banks that have entered into such a deal in the past include UBS, Credit Suisse and Julius Bär.

Migros Bank’s regulations also protect its employees from lawsuits, it was announced on Monday.

In recent years, the Swiss banking sector has come under the microscope of several countries which discovered that citizens were hiding money in Swiss accounts to avoid paying taxes.

The investigations in Germany were facilitated by the illicit sale of stolen Swiss bank data to several German states.

Banks have generally avoided criminal prosecution by settling complaints out of court. In the United States, the Swiss government was forced to intervene to set up a vast program of out-of-court settlement between the Department of Justice and several Swiss banks.

Despite efforts to clear the list of the Swiss banking sector, tax evasion investigations are still ongoing in some countries. UBS is awaiting a court verdict in France later this year, after appealing a € 4.5 billion tax evasion penalty imposed on the bank in 2019.



Source link

]]>
http://wbts-forum.org//swiss-bank-pays-to-settle-german-tax-evasion-investigation/feed/ 0
Eurozone bond yields rise as global sentiment improves http://wbts-forum.org//eurozone-bond-yields-rise-as-global-sentiment-improves/ http://wbts-forum.org//eurozone-bond-yields-rise-as-global-sentiment-improves/#respond Mon, 26 Apr 2021 07:10:38 +0000 http://wbts-forum.org//eurozone-bond-yields-rise-as-global-sentiment-improves/

Band Dhara Ranasinghe

LONDON, April 26 (Reuters)Eurozone bond yields edged up on Monday, reflecting stronger sentiment in global markets and a growing sense that the worst could be behind for an economy hit by coronaviruses.

Most 10-year bond yields in the currency bloc rose 1 to 2 basis points on the day, while yields on US Treasuries were also slightly higher.

As bond markets stabilized after a U.S.-led liquidation earlier this year, improving economic indicators and a resumption of the COVID-19 vaccination rollout have started to put some pressure on the increase in borrowing costs in the euro zone.

The past few weeks have seen an acceleration in European vaccinations, with major countries in the European Union rolling out vaccines at a rate similar to Britain. The EU is expected to meet its goal of vaccinating 70% of adults by the summer, according to NatWest Markets.

The 10-year German Bund yield was last up 2 basis points to -0.24% DE10YT = RR, not far from the seven-week highs reached last week. 30-year bond yields, at 0.31% DE30YT = RR, were near the highs of more than a year affected last week.

Andreas Billmeier, European economist Western Asset, said the uptrend in European bond yields should be gradual and fit into the bigger picture of a recovering economy.

“If you remove the momentum from US rates, you have an economic recovery and that should go hand in hand with higher rates.”

“Note that the ECB (European Central Bank) did not make a noise when yields rose between December and February, but only after volatility from the United States kicked in.”

The ECB stepped up the pace of its bond purchases in March to contain rising borrowing costs, driven by US Treasuries.

Italy, which reached an agreement with the European Commission on its stimulus package after days of intense discussions, paved the way for its submission to Brussels by the end of April.

“The positivity of the good allocation of European funds” has not yet fully fueled the BTP / Bund spread, and there is still room for significant tightening there, “Mizuho said in a note.

The Italian / German 10-year yield spread was 103 basis points DE10IT10YT = RR

On Friday evening, S&P raised Greece’s rating up a notch to ‘BB’, citing hopes of a rapid improvement in the country’s economic and fiscal performance as the adverse effects of the COVID-19 pandemic ‘attenuate. L4N2MG3SF

The yield on Greek 10-year bonds rose around 1bp to 0.90% GR10YT = RR in line with euro area peers.

(Reporting by Dhara Ranasinghe; Editing by Kirsten Donovan)

((Dhara.Ranasinghe@thomsonreuters.com; +442075422684;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



Source link

]]>
http://wbts-forum.org//eurozone-bond-yields-rise-as-global-sentiment-improves/feed/ 0
M&G Investments sees attractive investment opportunities in Asian equities http://wbts-forum.org//mg-investments-sees-attractive-investment-opportunities-in-asian-equities/ http://wbts-forum.org//mg-investments-sees-attractive-investment-opportunities-in-asian-equities/#respond Mon, 26 Apr 2021 06:36:58 +0000 http://wbts-forum.org//mg-investments-sees-attractive-investment-opportunities-in-asian-equities/ Bloomberg Selling Almost Useless Signals in the Unchartable Stock Market 2021 (Bloomberg) – If you bailed out from the Bollinger Bands, ran away from relative strength, or headed for the market directional indicator in 2021, you paid for it. investors doing anything other than buying have done them a disservice this year. In fact, when […]]]>


Bloomberg

Selling Almost Useless Signals in the Unchartable Stock Market 2021

(Bloomberg) – If you bailed out from the Bollinger Bands, ran away from relative strength, or headed for the market directional indicator in 2021, you paid for it. investors doing anything other than buying have done them a disservice this year. In fact, when applied to the S&P 500, 15 of 22 chart-based indicators tracked by Bloomberg actually lost money, according to back-testing data. And all of them do worse than a simple buy and hold strategy, which is up 11%. Of course, few investors use technical studies in isolation, and even when they do, they do. rarely rely on a single mapping technique to inform their decisions. But if anything, the exercise is reminiscent of the futility of qualifying a market leading in a year when the trip was essentially a one-way ticket. “What we’ve seen this year is a very strong rising market that hasn’t. get a lot of setbacks, ”said Larry Williams, 78, creator of the Williams% R indicator designed to capture a change in a safety’s momentum. A technique-based long-short strategy is down 7.8% since the end of December. “All of the overbought and oversold indicators, mine and anyone else’s, haven’t received a lot of buy signals, but a lot of sell”, it’s hard to resist the temptation to book profits and bail after the S&P 500’s best 12-month rally since the 1930s. Growing anxiety is a mountain of charts signaling a market that has reached its limits. Earlier this month, the index climbed 16% above its 200-day average, a feat that before December had only happened a handful of times in the past three decades. In addition, the relative strength index of the benchmark has exceeded 70 on a weekly and monthly basis, a sign that the market has risen too far, too fast. sell orders. Hedge funds, for example, came out this month, ditching tech stocks just days before Apple Inc. and Amazon.com Inc. released their financial results. bet of all. The S&P 500 has yet to cut more than 5% this year. At the same time, missing out on the big days is more punitive than ever. In the absence of the first five sessions, the index gain of 11% drops to 2%. “To try to guess when it’s a good time to be out of the market, you might as well head to Las Vegas,” said Mark Stoeckle, general manager. agent at Adams Funds. “There are just as many risks in doing this.” Bloomberg’s back-testing model buys the S&P 500 when an indicator signals a “buy” and holds it until a “sell” is generated. At that point, the index is sold and a short position is established and held until a buy is triggered. A strategy following RSI signals has fallen 10% this year. The damage came as stocks entered the year with frantic momentum that triggered a sell order. Trade has since been in place as the S&P 500 never retreated fast enough and long enough to buy flash. The moving average convergence / divergence indicator – better known as MACD – suffered a loss of 9 , 8%. Five of the nine trading signals the model produced were buys, and four of them lost money. In addition, the four brief recommendations were the losers. That is the cost of betting against momentum in a market where the S&P 500 has already eclipsed the average Wall Street strategist’s year-end target. Conditions were absorbed by the market with more force, or at best a pause, ”said Jeff deGraaf, co-founder of Renaissance Macro Research, which ranked as top technical analyst in Institutional Investor’s annual survey. for 11 consecutive years until 2015. “Overbought / oversold conditions are unnecessary without first defining the underlying market trend. Williams, who has been negotiating since 1962, agrees. Technical analysis tools aren’t broken, he says, but in a bull market as resilient as this one, investors need to use them in the right context. “You have to have a different tool, if you will, for a job that you ‘do,’ he says. “I have a hammer that can build a house, but if I use the hammer to dig a hole in the ground, it will be really difficult.” For more articles like this, please visit us at bloomberg.com with the most trusted source of business news. © 2021 Bloomberg LP



Source link

]]>
http://wbts-forum.org//mg-investments-sees-attractive-investment-opportunities-in-asian-equities/feed/ 0
Informa merges its financial intelligence activity with Novantas http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/ http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/#respond Mon, 26 Apr 2021 06:35:04 +0000 http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/ Globe Newswire Transactions related to the share buyback program Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted […]]]>


Globe Newswire

Transactions related to the share buyback program

Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted actions. The share buyback program is expected to be completed by June 30, 2021 and includes up to 200,000 shares. The following transactions were executed as part of the program from April 19, 2021 to April 23, 2021: Number of shares Average price (DKK) Total value (DKK) Cumulative at last announcement 115,000 237,524,833 April 19, 20211,8002,206,243,971,232 April 20, 20211,6002,217,643,548,22421 April 202122 April, 20211,600 1,5002,233,892,281,413,574,2243,422,11523 April 20211,4002,262,103,166,940 Total7,900 17,682,735 Accumulated under the program 122,900 255,207,568 The Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 225,877 treasury shares, corresponding to 0.34% of the total capital and voting rights. The share buyback program is implemented in accordance with Regulation (EU) No 596/2014 (“MAR”) and Commission Delegated Regulation (EU) 2016/1052, also known as the “Safe Harbor Regulation”. “. Further details on the terms of the share buyback program can be found in our corporate announcement no. 11 of February 23, 2021. About Genmab Genmab is an international biotechnology company whose primary goal is to improve the lives of cancer patients. Founded in 1999, Genmab is the creator of several approved therapeutic antibodies which are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next generation antibody technologies, expertise in antibody biology, translational research and data science and strategic partnerships. To create new therapies, Genmab uses its next generation antibody technologies, which are the result of its collaborative corporate culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of engineered antibody candidates, including bispecific T-cell engaging agents and next-generation immune checkpoint modulators, effector-enhanced antibodies, and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark, with locations in Utrecht, the Netherlands, Princeton, New Jersey, the United States and Tokyo, Japan. For more information, please visit Genmab.com. Contact: Marisol Peron, Senior Vice President, Global Investor Relations & Communications T: +1 609 524 0065; E: mmp@genmab.com For Investor Relations: Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This company announcement contains forward-looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from future results or performance expressed or implied in such statements. Important factors that could cause our actual results or performance to vary materially include, but are not limited to, risks associated with preclinical and clinical product development, uncertainties associated with the results and conduct of clinical trials, including unforeseen safety issues, uncertainties related to the product. manufacturing, lack of market acceptance of our products, inability to manage growth, competitive environment in relation to our industry and markets, inability to attract and retain suitably qualified personnel, inapplicability or lack of protection of our patents and rights, our relationships with affiliated entities, technological changes and developments that may render our products or technologies obsolete, and other factors. For a more in-depth discussion of these risks, please refer to the risk management sections of Genmab’s most recent financial reports, available at www.genmab.com and to the risk factors included in Genmab’s latest annual report on form 20-F and other documents filed. with the United States Securities and Exchange Commission (SEC), available at www.sec.gov. Genmab assumes no obligation to update or revise any forward-looking statements in this company announcement or to confirm such statements to reflect subsequent events or circumstances after the date of publication or in connection with actual results, unless the law requires it. Genmab A / S and / or its subsidiaries own the following brands: Genmab®; the Y-shaped Genmab® logo; Genmab in combination with the Y-shaped Genmab® logo; HuMax®; DuoBody®; DuoBody in combination with the DuoBody® logo; HexaBody®; HexaBody in combination with the HexaBody® logo; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its subsidiaries. DARZALEX® and DARZALEX FASPRO® are registered trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc. Company announcement no. 33CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A / SKalvebod Brygge 431560 Copenhagen VDenmark Attachments 210426_CA33_Transactions in connection with SBBP 26 April 210426_CA33_Appendix Specification for April 19-23



Source link

]]>
http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/feed/ 0
Food Ingredient Maker Tate & Lyle Plans to Divide Its Healthcare Business http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/ http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/#respond Mon, 26 Apr 2021 06:18:08 +0000 http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/ Globe Newswire Transactions related to the share buyback program Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted […]]]>


Globe Newswire

Transactions related to the share buyback program

Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted actions. The share buyback program is expected to be completed by June 30, 2021 and includes up to 200,000 shares. The following transactions were executed as part of the program from April 19, 2021 to April 23, 2021: Number of shares Average price (DKK) Total value (DKK) Cumulative at last announcement 115,000 237,524,833 April 19, 20211,8002,206,243,971,232 April 20, 20211,6002,217,643,548,22421 April 202122 April, 20211,600 1,5002,233,892,281,413,574,2243,422,11523 April 20211,4002,262,103,166,940 Total7,900 17,682,735 Accumulated under the program 122,900 255,207,568 The Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 225,877 treasury shares, corresponding to 0.34% of the total capital and voting rights. The share buyback program is implemented in accordance with Regulation (EU) No 596/2014 (“MAR”) and Commission Delegated Regulation (EU) 2016/1052, also known as the “Safe Harbor Regulation”. “. Further details on the terms of the share buyback program can be found in our corporate announcement no. 11 of February 23, 2021. About Genmab Genmab is an international biotechnology company whose primary goal is to improve the lives of cancer patients. Founded in 1999, Genmab is the creator of several approved therapeutic antibodies which are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next generation antibody technologies, expertise in antibody biology, translational research and data science and strategic partnerships. To create new therapies, Genmab uses its next generation antibody technologies, which are the result of its collaborative corporate culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of engineered antibody candidates, including bispecific T-cell engaging agents and next-generation immune checkpoint modulators, effector-enhanced antibodies, and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark, with locations in Utrecht, the Netherlands, Princeton, New Jersey, the United States and Tokyo, Japan. For more information, please visit Genmab.com. Contact: Marisol Peron, Senior Vice President, Global Investor Relations & Communications T: +1 609 524 0065; E: mmp@genmab.com For Investor Relations: Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This company announcement contains forward-looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from future results or performance expressed or implied in such statements. Important factors that could cause our actual results or performance to vary materially include, but are not limited to, risks associated with preclinical and clinical product development, uncertainties associated with the results and conduct of clinical trials, including unforeseen safety issues, uncertainties related to the product. manufacturing, lack of market acceptance of our products, inability to manage growth, competitive environment in relation to our industry and markets, inability to attract and retain suitably qualified personnel, inapplicability or lack of protection of our patents and rights, our relationships with affiliated entities, technological changes and developments that may render our products or technologies obsolete, and other factors. For a more in-depth discussion of these risks, please refer to the risk management sections of Genmab’s most recent financial reports, available at www.genmab.com and to the risk factors included in Genmab’s latest annual report on form 20-F and other documents filed. with the United States Securities and Exchange Commission (SEC), available at www.sec.gov. Genmab assumes no obligation to update or revise any forward-looking statements in this company announcement or to confirm such statements to reflect subsequent events or circumstances after the date of publication or in connection with actual results, unless the law requires it. Genmab A / S and / or its subsidiaries own the following brands: Genmab®; the Y-shaped Genmab® logo; Genmab in combination with the Y-shaped Genmab® logo; HuMax®; DuoBody®; DuoBody in combination with the DuoBody® logo; HexaBody®; HexaBody in combination with the HexaBody® logo; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its subsidiaries. DARZALEX® and DARZALEX FASPRO® are registered trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc. Company announcement no. 33CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A / SKalvebod Brygge 431560 Copenhagen VDenmark Attachments 210426_CA33_Transactions in connection with SBBP 26 April 210426_CA33_Appendix Specification for April 19-23



Source link

]]>
http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/feed/ 0
Dollar climbs lower on bets US reduction remains distant http://wbts-forum.org//dollar-climbs-lower-on-bets-us-reduction-remains-distant/ http://wbts-forum.org//dollar-climbs-lower-on-bets-us-reduction-remains-distant/#respond Mon, 26 Apr 2021 06:11:15 +0000 http://wbts-forum.org//dollar-climbs-lower-on-bets-us-reduction-remains-distant/ By Stanley White TOKYO (Reuters) – The dollar fell slightly on Monday amid speculation that U.S. Federal Reserve Chairman Jerome Powell will avoid talking about cutting bond purchases at a policy meeting this week. The euro hit a near two-month high against the greenback before data on Monday predicted improving sentiment for German businesses, which […]]]>


By Stanley White

TOKYO (Reuters) – The dollar fell slightly on Monday amid speculation that U.S. Federal Reserve Chairman Jerome Powell will avoid talking about cutting bond purchases at a policy meeting this week.

The euro hit a near two-month high against the greenback before data on Monday predicted improving sentiment for German businesses, which would bolster hopes for a brighter economic outlook.

Powell will likely have to ask himself whether improving labor market and rising coronavirus vaccinations justify the withdrawal of monetary easing, but most analysts expect him to say such talk is premature, which would put downward pressure on Treasury yields and the dollar.

do all work online

“The dollar is expected to continue to decline in line with the growing strength of the global economy,” analysts at the Commonwealth Bank of Australia wrote in a research note.

“We expect the Fed policy meeting to be a non-event for the dollar. The US economy is far from reaching the threshold of ‘substantial progress’ for the Fed to reduce its asset purchases.

The dollar settled at 107.75 yen, close to its lowest since March 4.

gawdo.com

The euro rose to $ 1.2110, adding to gains made on Friday after positive data on European services and manufacturing activity.

A survey by the German Ifo institute, scheduled for later Monday, is expected to show that business conditions have continued to improve in Europe’s largest economy.

The British pound was listed at $ 1.3897, adding to a 0.3% gain in the previous session.

The dollar was little changed at 0.9128 Swiss francs, close to a two-month low.

The Fed’s next meeting ends Wednesday, and while no major policy changes are expected, investors will pay close attention to Powell’s comments after the meeting.

Rising coronavirus vaccination rates and improving economic outlook are reasons for optimism, but many traders and analysts say Powell is likely to reiterate his commitment to keeping easy policy in place for an extended period. .

U.S. funds recently sold the dollar against the yen in Asian trading, which is a further sign that major investors expect lower U.S. Treasury yields to push the dollar lower, said. some traders in Tokyo.

In emerging markets, traders are watching the Turkish lira to see if it will test its all-time low of 8.58 per dollar amid deteriorating relations with the United States and concerns about an accommodating central bank governor. The lira was last listed at 8.4285.

The onshore yuan edged up to 6.4866 to the dollar, just short of a six-week high.

Elsewhere, the Australian and New Zealand dollars hit one-month highs, but are expected to keep pace with global commodity prices, traders said.

In the cryptocurrency market, Bitcoin recovered the $ 50,000 mark and little rival Ether rose, recouping some of their losses from last week triggered by US President Joe Biden’s plan to raise taxes on capital gains for wealthy investors.

(Reporting by Stanley White; editing by Richard Pullin)



Source link

]]>
http://wbts-forum.org//dollar-climbs-lower-on-bets-us-reduction-remains-distant/feed/ 0
Novatek shareholders approve $ 11 billion in external financing for Arctic LNG 2 http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/ http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/#respond Mon, 26 Apr 2021 05:23:04 +0000 http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/ Shareholders of Russia’s second-largest gas producer, Novatek, have approved $ 11 billion in external financing for the Arctic LNG 2 project on which Novatek has pledged its 60% stake in the project as collateral. The approval came on April 23 at the company’s annual general meeting of shareholders. Making the announcement, Novatek CEO Leonid Mikhelson […]]]>


Shareholders of Russia’s second-largest gas producer, Novatek, have approved $ 11 billion in external financing for the Arctic LNG 2 project on which Novatek has pledged its 60% stake in the project as collateral.

The approval came on April 23 at the company’s annual general meeting of shareholders. Making the announcement, Novatek CEO Leonid Mikhelson said the responsibility for fundraising would be divided in three ways between Russia, China and the tandem of Japan and Europe acting together.

The $ 21 billion project, which received final investment approval in 2019, is expected to start production in 2023 as Novatek expands its LNG exports east and west along the coast now navigable arctic of Russia.

Arctic LNG 2 will reach full capacity of nearly 20 mtpa in 2026, according to the company.

Novatek has a 60% stake in the project, with the remaining 40% being split equally between France’s Total, China National Petroleum Corporation, China’s CNOOC and the Japan Arctic LNG consortium, made up of Mitsui & Co. and the state-owned JOGMEC, officially known as Japan Oil, Gas, and Metals National Corp.

In April, Novatek said it would pledge the 60% stake as collateral for long-term funding, according to Reuters.

Financial media reports conducted by Reuters said in September that the project had already attracted enough international capital to cover almost all of the $ 11 billion sought. Quoting a document first cited by Reuters, S&P Global reported that “the national investment bank and credit agency Bpifrance SA has offered $ 700 million in credit financing; China Development Bank and German bank Euler Hermes would offer a $ 5 billion facility and a $ 300 million covered facility, respectively.

“Other state-backed institutions would have included the Japanese Bank for International Cooperation with a $ 2.5 billion facility, Italian SACE with a $ 1 billion covered facility, and an anonymous Russian bank with $ 1 billion, $ 5 billion, ”S&P Global reported, citing Reuters figures.

Russian state bank Sberbank approved funding of up to 3 billion euros ($ 3.5 billion) in January, Reuters wrote.

At the end of February, Novatek signed an agreement with Chinese group Shenergy to deliver more than 3 million tonnes of LNG to terminals in China over 15 years, as the Russian gas producer continued to align buyers with the intention of expand its presence in the Asia-Pacific region. Region.

“Our LNG business strategy is to diversify our customer base and target end consumers in the rapidly growing Asia-Pacific region,” Mikhelson said in a statement released at the time. “The Chinese market is one of the key regions of our LNG marketing strategy, and we plan to further increase our supplies of liquefied natural gas there.”

In January, the Russian Arctic-class LNG carrier Christophe de Margerie made the very first round trip along the Northern Kara Sea Sea Route to China, proving that navigation is possible all year round and giving Russia the opportunity to set attractive prices for its LNG exports.

Russia’s largest independent gas producer, Novatek entered the global LNG market by launching the Yamal LNG project in 2017. The upstream activities of the company are concentrated mainly in the Yamal-Nenets Autonomous Region, which is the largest natural gas production area in the world, accounting for about 80% of Russia’s natural gas production and about 15% of global gas production.

In the first quarter of 2021, Novatek produced 158.1 million BOE, including 20.15 Gcm of natural gas and 3,129 thousand tonnes of liquids (gas condensate and crude oil). This represents a 5.3% increase in total hydrocarbons produced (BOE) in the first quarter of 2021 compared to the first quarter of 2020, according to a press release from the company.

Novatek said capital spending on the 19.8 mtpa LNG project will reach $ 21.3 billion. Arctic LNG 2 is expected to start its first train in 2023; the second and third trains will launch in 2024 and 2026 respectively, according to the company’s website.



Source link

]]>
http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/feed/ 0
Merkel’s inability to tackle Germany’s climate woes risks boosting green energy http://wbts-forum.org//merkels-inability-to-tackle-germanys-climate-woes-risks-boosting-green-energy/ http://wbts-forum.org//merkels-inability-to-tackle-germanys-climate-woes-risks-boosting-green-energy/#respond Mon, 26 Apr 2021 05:00:00 +0000 http://wbts-forum.org//merkels-inability-to-tackle-germanys-climate-woes-risks-boosting-green-energy/ A reliance on coal for energy and a reluctance to engage in heavy industry have hampered the climate efforts of the world’s sixth largest carbon emitter. About 44% of German energy production came from renewables in 2020, but a quarter still came from lignite (also known as lignite) and hard coal – dirty energy sources […]]]>


A reliance on coal for energy and a reluctance to engage in heavy industry have hampered the climate efforts of the world’s sixth largest carbon emitter.

About 44% of German energy production came from renewables in 2020, but a quarter still came from lignite (also known as lignite) and hard coal – dirty energy sources that are nearly obsolete in the Kingdom. -United. The need for coal was not helped by Merkel’s government which approved the phase-out of nuclear power following the Fukushima disaster.

“Emissions from the electricity sector have not increased despite phasing out nuclear, but neither have they decreased,” said Jutta Paulus, a Green MEP. “Nuclear power went out, coal and gas power plants continued to operate, and the gap was closed by renewables. If the nuclear phase-out had been postponed, then we would have seen a much larger decrease, but I’m sure German society would not have agreed to keep nuclear on the grid.

Go green

Critics say the Merkel government has sacrificed its climate ambitions to help heavy industries that underpin the German economy, like its auto giants. The reduction in transport emissions has been a major weak point, while a package of 50 billion euros in 2019 to accelerate the country’s progress was deemed insufficient.

“Over the past 15 years, the industry has strongly opposed any kind of climate protection measure,” says Claudia Kemfert, environmental economist at DIW Berlin. “The CDU was under a lot of pressure, that’s for sure. Now is the time for a change and the industry itself is changing its mind. “

Just as Merkel’s CDU has fallen behind on climate goals, the Greens have become a serious force in German politics. After being controlled by the hard-line and radical Fundis, the Greens are now led by the more centrist Realo group and will likely be part of the next coalition government.



Source link

]]>
http://wbts-forum.org//merkels-inability-to-tackle-germanys-climate-woes-risks-boosting-green-energy/feed/ 0